课题基金 / 基金详情

项目摘要

项目成果

KATHRYN HIRST的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):本申请寻求资金,以完成自2002年以来在U 01合作协议机制下由治疗或预防儿童2型糖尿病研究(STOPP-T2 D)联盟进行的当前方案。要求再提供4年的资金,以便:(1)完成当前的协议和数据库质量控制,(2)启动对结果数据和方法的分析和报告,(3)将数据存档并转移到NIDDK中央储存库。这些研究以少数民族青年为对象。由15个临床中心组成的治疗研究组正在实施两项方案。(1)TODAY是一项多中心、3组、前瞻性、随机、部分盲态临床试验。主要目的是评价维持血糖控制的3种治疗的安全性和有效性。年龄为10-17岁的受试者(迄今为止N=629)在4年内招募,在诊断为T2 D后2年内随机分配,并将随访2-6年。招募计划于2008年9月1日结束,最终随机化和基线数据收集于2009年2月28日结束,最终随访于2011年2月28日结束。(2)TODAY遗传学研究方案将招募另外2500名在18岁生日前被诊断患有T2 D的参与者。主要目的是收集血液和表型信息,用于探索候选基因与2型糖尿病,以及肥胖,胰岛素抵抗和胰岛素抵抗的心血管并发症之间的关系。招募工作预计将于2008年夏末开始,持续到2011年2月28日。预防研究小组正在42所中学进行健康初级预防试验。一系列试点和可行性研究有助于确定和制定研究目标和干预措施。主要目的是减少风险因素,如肥胖,与对照学校相比,在干预中与T2 D的发展相关。干预措施改变了整个学校的营养和体育活动环境,包括教育和宣传活动。在基线(2006年秋季)测量了6000多名六年级学生;在八年级结束时(2009年春季)收集最终数据。 公共卫生相关性:儿童人群中2型糖尿病(T2 D)和肥胖(T2 D的主要风险因素)的发病率最近急剧上升,对我们的医疗保健系统产生了重要影响。以前的T2 D治疗和预防研究主要针对成人。STOPP-T2 D联盟代表了第一个大规模的联邦资助的努力进行研究,以进一步我们的知识和了解这些问题及其解决方案的儿童和青少年之一。
英文摘要
DESCRIPTION (provided by applicant): This application seeks funding to complete the current protocols being conducted by the Studies to Treat Or Prevent Pediatric Type 2 Diabetes (STOPP-T2D) consortium under the U01 cooperative agreement mechanism since 2002. Funding is requested for an additional 4 years to: (1) complete the current protocols and database quality control, (2) initiate analysis and report of outcome data and methods, and (3) archive and transfer the data to the NIDDK central repositories. The studies target minority youth. The treatment study group of 15 clinical centers is conducting two protocols. (1) TODAY is a multi-center, 3-arm, prospective, randomized, partially-blinded clinical trial. The primary object is to evaluate the safety and efficacy of 3 treatments to maintain glycemic control. Subjects (N=629 to date) aged 10-17 were recruited over a 4-year period, randomized within 2 years of diagnosis of T2D, and will be followed for 2-6 years. Recruitment is scheduled to end September 1, 2008, final randomization and baseline data collection on February 28, 2009, and final follow-up on February 28, 2011. (2) The TODAY genetics study protocol will enroll an additional 2500 participants who were diagnosed with T2D prior to their 18th birthday. The primary objective is to collect blood and phenotypic information to be used to explore relationships between candidate genes and type 2 diabetes, as well as obesity, insulin resistance, and cardiovascular complications of insulin resistance. Recruitment is expected to start in late summer 2008 and continue until February 28, 2011. The prevention study group is conducting the HEALTHY primary prevention trial in 42 middle schools. A series of pilot and feasibility studies helped to define and develop study objectives and intervention. The primary objective is to reduce risk factors, such as obesity, associated with the development of T2D in intervention compared to control schools. The intervention changes the nutrition and physical activity environment throughout the school and includes educational and promotional events. Over 6000 6th graders were measured at baseline (fall 2006); final data are collected at end of 8th grade (spring 2009). PUBLIC HEALTH RELEVANCE: The recent and precipitous rises in rates of type 2 diabetes (T2D) and in obesity (the primary risk factor for T2D) in the pediatric population have important ramifications for our health care system. Previous research of treatment and prevention of T2D targeted mainly adults. The STOPP-T2D consortium represents one of the first large-scale federally-funded efforts to conduct studies to further our knowledge and understanding of these problems and their solution in children and adolescents.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The Studies to Treat Or Prevent Pediatric Type 2 Diabetes--STOPP-T2D
  • 批准号:
    8039669
  • 项目类别:
  • 资助金额:
    $110.26万
  • 财政年份:
    2010
  • 负责人:
    KATHRYN HIRST
  • 依托单位:
Core--Data management
Statistics Center for Pediatric Type 2 Diabetes Therapy
  • 批准号:
    6666116
  • 项目类别:
  • 资助金额:
    $48.72万
  • 财政年份:
    2001
  • 负责人:
    KATHRYN HIRST
  • 依托单位:
Statistics Center for Pediatric Type 2 Diabetes Therapy
  • 批准号:
    7497286
  • 项目类别:
  • 资助金额:
    $22.63万
  • 财政年份:
    2001
  • 负责人:
    KATHRYN HIRST
  • 依托单位:
海外基金